Capivasertib (AZD5363) shows a constructive pharmacokinetic and toxicity profile in a BT474c breast cancer xenograft mouse model [124] and exhibits a promising efficacy in targeting castration resistant prostate cancer[125], Her2+ breast cancer models and tumors harboring the Akt1 E17K mutation [126]. This evidence concerns the gene AKT1 and prostate cancer.